Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,385 | 1,938 | 2,879 | 319 | 1,091 |
| Receivables | 3 | N/A | 2 | 2 | 5 |
| TOTAL | $1,988 | $2,685 | $3,738 | $1,067 | $2,755 |
| Non-Current Assets | |||||
| PPE Net | 91 | 97 | N/A | N/A | N/A |
| Other Non-Current Assets | 887 | 942 | 997 | 1,053 | 0 |
| TOTAL | $978 | $1,039 | $997 | $1,053 | $N/A |
| Total Assets | $2,966 | $3,724 | $4,735 | $2,120 | $2,755 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 613 | 843 | 809 | 831 | 516 |
| Accrued Expenses | 200 | 78 | 265 | 231 | 176 |
| TOTAL | $813 | $921 | $1,074 | $1,062 | $692 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $813 | $921 | $1,074 | $1,062 | $692 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,378 | 2,232 | 2,195 | 1,640 | 1,601 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -924,622 | -923,729 | -922,570 | -921,519 | -920,446 |
| TOTAL | $2,153 | $2,803 | $3,661 | $1,058 | $2,063 |
| Total Liabilities And Equity | $2,966 | $3,724 | $4,735 | $2,120 | $2,755 |